Molecular Imaging and Updated Diagnostic Criteria in Lewy Body Dementias

作者：Bohnen Nicolaas I^*; Mueller Martijn L T M; Frey Kirk A

来源：Current Neurology and Neuroscience Reports, 2017, 17(10): 73.

DOI：10.1007/s11910-017-0789-z

• Acetylcholine
• beta-Amyloid
• DementiawithLewy bodies
• Diagnostic criteria
• Dopamine
• Parkinson disease with dementia

Purpose of Review The aims of the study were to review recent advances in molecular imaging in the Lewy body dementias (LBD) and determine if these may support the clinical but contested temporal profile distinction between Parkinson disease (PD) with dementia (PDD) versus dementia with Lewy bodies (DLB).
Recent Findings There do not appear to be major regional cerebral metabolic or neurotransmitter distinctions between PDD and DLB. However, recent studies highlight the relative discriminating roles of Alzheimer proteinopathies. PDD patients have lower cortical beta-amyloid deposition than DLB. Preliminary tau PET studies suggest a gradient of increasing tau binding from cognitively normal PD (absent to lowest) to cognitively impaired PD (low) to DLB (intermediate) to Alzheimer disease (AD; highest). However, tau binding in DLB, including the medial temporal lobe, is substantially lower than in AD.
Summary Alzheimer-type proteinopathies appear to be more common in DLB compared to PDD with relative but no absolute differences. Given the spectrum of overlapping pathologies, future alpha-synuclein ligands are expected to have the best potential to distinguish the LBD from pure AD.

• 出版日期2017-10